IL6R and neoplasm: In addition, systematic administration of IL-6/IL-6R antagonist(s) with MCT-1 inhibitor(s) may promote immune cell infiltration to advance therapeutics against tumor heterogeneity and aggressiveness, with fewer adverse effect(s).